Core Viewpoint - Changfeng Pharmaceutical has successfully completed the first patient enrollment for its self-developed bronchial valve lung volume reduction device, marking the official start of the clinical validation phase aimed at providing a minimally invasive treatment option for patients with emphysema and chronic obstructive pulmonary disease (COPD) [1] Company Summary - Changfeng Pharmaceutical's stock rose nearly 3%, currently trading at 29.2 HKD with a transaction volume of 5.3645 million HKD [1] - The successful completion of the first patient enrollment signifies the entry of this innovative minimally invasive device into the clinical validation stage [1] Industry Summary - The device targets unmet clinical needs in the management of emphysema, which is characterized by dynamic hyperinflation and limited activity [1] - The clinical study will focus on safety monitoring during the perioperative period and multi-dimensional assessments of imaging and lung function, with key indicators including device-related safety, technical success rate, and changes in clinical outcomes such as FEV1, RV, 6MWD, and SGRQ [1] - The research data will form an auditable evidence chain for future registration strategies and commercialization decisions [1]
港股异动 | 长风药业(02652)午前涨近3% 公司治疗肺气肿领域的微创介入器械完成首例入组